Elanco Animal Health (NYSE:ELAN) Sets New 1-Year Low - Time to Sell?

Elanco Animal Health Incorporated (NYSE:ELAN - Get Free Report)'s stock price reached a new 52-week low on Thursday . The stock traded as low as $9.75 and last traded at $9.77, with a volume of 4155953 shares. The stock had previously closed at $10.77.

Analyst Ratings Changes

A number of brokerages have commented on ELAN. UBS Group decreased their price objective on Elanco Animal Health from $18.00 to $17.00 and set a "buy" rating on the stock in a report on Wednesday, February 26th. Piper Sandler decreased their price target on shares of Elanco Animal Health from $16.00 to $12.00 and set a "neutral" rating on the stock in a research note on Thursday, March 6th. Stifel Nicolaus dropped their price objective on shares of Elanco Animal Health from $18.00 to $16.00 and set a "buy" rating for the company in a research note on Friday, February 21st. Morgan Stanley decreased their target price on shares of Elanco Animal Health from $14.00 to $13.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 26th. Finally, Barclays dropped their price target on shares of Elanco Animal Health from $20.00 to $19.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. Four equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and a consensus target price of $15.17.

Elanco Animal Health Stock Performance

The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.31 and a current ratio of 2.55. The company has a market cap of $4.13 billion, a P/E ratio of 20.79, a P/E/G ratio of 2.50 and a beta of 1.44. The stock's fifty day moving average price is $10.82 and its two-hundred day moving average price is $12.16.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.01 billion. During the same period in the prior year, the business posted $0.08 EPS. The company's revenue for the quarter was down 1.4% compared to the same quarter last year. As a group, equities analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insiders Place Their Bets

In related news, Director Lawrence Erik Kurzius bought 10,000 shares of the business's stock in a transaction on Tuesday, March 11th. The shares were purchased at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now directly owns 111,459 shares of the company's stock, valued at approximately $1,136,881.80. This represents a 9.86 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this link. Insiders own 0.57% of the company's stock.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. FMR LLC increased its holdings in Elanco Animal Health by 1,153.6% in the 4th quarter. FMR LLC now owns 40,232,327 shares of the company's stock worth $487,213,000 after purchasing an additional 37,022,891 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in shares of Elanco Animal Health by 6.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 17,900,987 shares of the company's stock valued at $216,774,000 after buying an additional 1,074,274 shares during the period. Shapiro Capital Management LLC increased its stake in shares of Elanco Animal Health by 7.5% in the fourth quarter. Shapiro Capital Management LLC now owns 12,356,702 shares of the company's stock valued at $149,640,000 after buying an additional 862,900 shares during the period. Magnetar Financial LLC raised its holdings in Elanco Animal Health by 13.7% in the 4th quarter. Magnetar Financial LLC now owns 12,032,325 shares of the company's stock valued at $145,711,000 after buying an additional 1,454,082 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Elanco Animal Health by 76.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 10,057,656 shares of the company's stock worth $147,747,000 after buying an additional 4,361,799 shares during the period. 97.48% of the stock is currently owned by institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.